2
|
Mellahi K, Cambay F, Brochu D, Gilbert M, Perrier M, Ansorge S, Durocher Y, Henry O. Process development for an inducible rituximab-expressing Chinese hamster ovary cell line. Biotechnol Prog 2018; 35:e2742. [PMID: 30414355 DOI: 10.1002/btpr.2742] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2018] [Revised: 10/25/2018] [Accepted: 10/31/2018] [Indexed: 12/12/2022]
Abstract
Inducible mammalian expression systems are becoming increasingly available and are not only useful for the production of cytotoxic/cytostatic products, but also confer the unique ability to uncouple the growth and production phases. In this work, we have specifically investigated how the cell culture state at the time of induction influences the cumate-inducible expression of recombinant rituximab by a GS-CHO cell line. To this end, cells grown in batch and fed-batch cultures were induced at increasing cell densities (1 to 10 × 10 6 cells/mL). In batch, the cell specific productivity and the product yield were found to reduce with increasing cell density at induction. A dynamic feeding strategy using a concentrated nutrient solution applied prior and postinduction allowed to significantly increase the integral of viable cells and led to a 3-fold increase in the volumetric productivity (1.2 g/L). The highest product yields were achieved for intermediate cell densities at induction, as cultures induced during the late exponential phase (10 × 10 6 cells/mL) were associated with a shortened production phase. The final glycosylation patterns remained however similar, irrespective of the cell density at induction. The kinetics of growth and production in a 2 L bioreactor were largely comparable to shake flasks for a similar cell density at induction. The degree of galactosylation was found to decrease over time, but the final glycan distribution at harvest was consistent to that of the shake flasks cultures. Taken together, our results provide useful insights for the rational development of fed-batch cell culture processes involving inducible CHO cells. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 35: e2742, 2019.
Collapse
Affiliation(s)
- Kahina Mellahi
- Dept. of Chemical Engineering, École Polytechnique de Montréal, Montréal, QC, H3C 3A7
| | - Florian Cambay
- Dept. of Chemical Engineering, École Polytechnique de Montréal, Montréal, QC, H3C 3A7
| | - Denis Brochu
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON
| | - Michel Gilbert
- Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, ON
| | - Michel Perrier
- Dept. of Chemical Engineering, École Polytechnique de Montréal, Montréal, QC, H3C 3A7
| | - Sven Ansorge
- Human Health Therapeutics Research Center, National Research Council Canada, Montréal, QC
| | - Yves Durocher
- Human Health Therapeutics Research Center, National Research Council Canada, Montréal, QC
| | - Olivier Henry
- Dept. of Chemical Engineering, École Polytechnique de Montréal, Montréal, QC, H3C 3A7
| |
Collapse
|
3
|
Gupta SK, Srivastava SK, Sharma A, Nalage VHH, Salvi D, Kushwaha H, Chitnis NB, Shukla P. Metabolic engineering of CHO cells for the development of a robust protein production platform. PLoS One 2017; 12:e0181455. [PMID: 28763459 PMCID: PMC5538670 DOI: 10.1371/journal.pone.0181455] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Accepted: 07/01/2017] [Indexed: 12/12/2022] Open
Abstract
Chinese hamster ovary (CHO) cells are the most preferred mammalian host used for the bio-pharmaceutical production. A major challenge in metabolic engineering is to balance the flux of the tuned heterogonous metabolic pathway and achieve efficient metabolic response in a mammalian cellular system. Pyruvate carboxylase is an important network element for the cytoplasmic and mitochondrial metabolic pathway and efficiently contributes in enhancing the energy metabolism. The lactate accumulation in cell culture can be reduced by re-wiring of the pyruvate flux in engineered cells. In the present work, we over-expressed the yeast cytosolic pyruvate carboxylase (PYC2) enzyme in CHO cells to augment pyruvate flux towards the TCA cycle. The dual selection strategy is adopted for the screening and isolation of CHO clones containing varying number of PYC2 gene load and studied their cellular kinetics. The enhanced PYC2 expression has led to enhanced pyruvate flux which, thus, allowed reduced lactate accumulation up to 4 folds and significant increase in the cell density and culture longevity. With this result, engineered cells have shown a significant enhanced antibody expression up to 70% with improved product quality (~3 fold) as compared to the parental cells. The PYC2 engineering allowed overall improved cell performance with various advantages over parent cells in terms of pyruvate, glucose, lactate and cellular energy metabolism. This study provides a potential expression platform for a bio-therapeutic protein production in a controlled culture environment.
Collapse
Affiliation(s)
- Sanjeev Kumar Gupta
- Advanced Biotech Lab, Ipca Laboratories Ltd., Plot#125, Kandivli Industrial Estate, Kandivli (west), Mumbai, Maharashtra, India
- Enzyme Technology and Protein Bioinformatics Laboratory, Department of Microbiology, Maharshi Dayanand University, Rohtak, Haryana-India
| | - Santosh K. Srivastava
- Advanced Biotech Lab, Ipca Laboratories Ltd., Plot#125, Kandivli Industrial Estate, Kandivli (west), Mumbai, Maharashtra, India
| | - Ankit Sharma
- Advanced Biotech Lab, Ipca Laboratories Ltd., Plot#125, Kandivli Industrial Estate, Kandivli (west), Mumbai, Maharashtra, India
| | - Vaibhav H. H. Nalage
- Advanced Biotech Lab, Ipca Laboratories Ltd., Plot#125, Kandivli Industrial Estate, Kandivli (west), Mumbai, Maharashtra, India
| | - Darshita Salvi
- Advanced Biotech Lab, Ipca Laboratories Ltd., Plot#125, Kandivli Industrial Estate, Kandivli (west), Mumbai, Maharashtra, India
| | - Hiralal Kushwaha
- Advanced Biotech Lab, Ipca Laboratories Ltd., Plot#125, Kandivli Industrial Estate, Kandivli (west), Mumbai, Maharashtra, India
| | - Nikhil B. Chitnis
- Advanced Biotech Lab, Ipca Laboratories Ltd., Plot#125, Kandivli Industrial Estate, Kandivli (west), Mumbai, Maharashtra, India
| | - Pratyoosh Shukla
- Enzyme Technology and Protein Bioinformatics Laboratory, Department of Microbiology, Maharshi Dayanand University, Rohtak, Haryana-India
- * E-mail:
| |
Collapse
|
4
|
Torkashvand F, Vaziri B, Maleknia S, Heydari A, Vossoughi M, Davami F, Mahboudi F. Designed Amino Acid Feed in Improvement of Production and Quality Targets of a Therapeutic Monoclonal Antibody. PLoS One 2015; 10:e0140597. [PMID: 26480023 PMCID: PMC4610691 DOI: 10.1371/journal.pone.0140597] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Accepted: 09/27/2015] [Indexed: 11/18/2022] Open
Abstract
Cell culture feeds optimization is a critical step in process development of pharmaceutical recombinant protein production. Amino acids are the basic supplements of mammalian cell culture feeds with known effect on their growth promotion and productivity. In this study, we reported the implementation of the Plackett-Burman (PB) multifactorial design to screen the effects of amino acids on the growth promotion and productivity of a Chinese hamster ovary DG-44 (CHO-DG44) cell line producing bevacizumab. After this screening, the amino acid combinations were optimized by the response surface methodology (RSM) to determine the most effective concentration in feeds. Through this strategy, the final monoclonal antibody (mAb) titre was enhanced by 70%, compared to the control group. For this particular cell line, aspartic acid, glutamic acid, arginine and glycine had the highest positive effects on the final mAb titre. Simultaneously, the impact of the designed amino acid feed on some critical quality attributes of bevacizumab was examined in the group with highest productivity. The product was analysed for N-glycan profiles, charge variant distribution, and low molecular weight forms. The results showed that the target product quality has been improved using this feeding strategy. It was shown how this strategy could significantly diminish the time and number of experiments in identifying the most effective amino acids and related concentrations in target product enhancement. This model could be successfully applied to other components of culture media and feeds.
Collapse
Affiliation(s)
| | - Behrouz Vaziri
- Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
- * E-mail: (BV); (FM)
| | - Shayan Maleknia
- Process Development Department, Aryogen Biopharma Inc., Alborz, Iran
| | - Amir Heydari
- Department of Chemical & Petroleum Engineering, Biochemical & Bioenvironmental Research Center Sharif University of Technology, Tehran, Iran
| | - Manouchehr Vossoughi
- Department of Chemical & Petroleum Engineering, Biochemical & Bioenvironmental Research Center Sharif University of Technology, Tehran, Iran
| | - Fatemeh Davami
- Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
| | - Fereidoun Mahboudi
- Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
- * E-mail: (BV); (FM)
| |
Collapse
|
5
|
Campbell A, Brieva T, Raviv L, Rowley J, Niss K, Brandwein H, Oh S, Karnieli O. Concise Review: Process Development Considerations for Cell Therapy. Stem Cells Transl Med 2015; 4:1155-63. [PMID: 26315572 DOI: 10.5966/sctm.2014-0294] [Citation(s) in RCA: 98] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2014] [Accepted: 05/20/2015] [Indexed: 11/16/2022] Open
Abstract
UNLABELLED The development of robust and well-characterized methods of production of cell therapies has become increasingly important as therapies advance through clinical trials toward approval. A successful cell therapy will be a consistent, safe, and effective cell product, regardless of the cell type or application. Process development strategies can be developed to gain efficiency while maintaining or improving safety and quality profiles. This review presents an introduction to the process development challenges of cell therapies and describes some of the tools available to address production issues. This article will provide a summary of what should be considered to efficiently advance a cellular therapy from the research stage through clinical trials and finally toward commercialization. The identification of the basic questions that affect process development is summarized in the target product profile, and considerations for process optimization are discussed. The goal is to identify potential manufacturing concerns early in the process so they may be addressed effectively and thus increase the probability that a therapy will be successful. SIGNIFICANCE The present study contributes to the field of cell therapy by providing a resource for those transitioning a potential therapy from the research stage to clinical and commercial applications. It provides the necessary steps that, when followed, can result in successful therapies from both a clinical and commercial perspective.
Collapse
Affiliation(s)
- Andrew Campbell
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada; Thermo Fisher Scientific, Inc., Grand Island, New York, USA; Celgene Cellular Therapeutics, Warren, New Jersey, USA; Pluristem Therapeutics Inc., Haifa, Israel; Rooster Bio Inc., Frederick, Maryland, USA; Novartis Pharmaceuticals, Morris Plains, New Jersey, USA; Pall Life Sciences (division of Pall Corp), Port Washington, New York, USA; Stem Cell Group, Bioprocessing Technology Institute, A*STAR, Singapore, Singapore
| | - Thomas Brieva
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada; Thermo Fisher Scientific, Inc., Grand Island, New York, USA; Celgene Cellular Therapeutics, Warren, New Jersey, USA; Pluristem Therapeutics Inc., Haifa, Israel; Rooster Bio Inc., Frederick, Maryland, USA; Novartis Pharmaceuticals, Morris Plains, New Jersey, USA; Pall Life Sciences (division of Pall Corp), Port Washington, New York, USA; Stem Cell Group, Bioprocessing Technology Institute, A*STAR, Singapore, Singapore
| | - Lior Raviv
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada; Thermo Fisher Scientific, Inc., Grand Island, New York, USA; Celgene Cellular Therapeutics, Warren, New Jersey, USA; Pluristem Therapeutics Inc., Haifa, Israel; Rooster Bio Inc., Frederick, Maryland, USA; Novartis Pharmaceuticals, Morris Plains, New Jersey, USA; Pall Life Sciences (division of Pall Corp), Port Washington, New York, USA; Stem Cell Group, Bioprocessing Technology Institute, A*STAR, Singapore, Singapore
| | - Jon Rowley
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada; Thermo Fisher Scientific, Inc., Grand Island, New York, USA; Celgene Cellular Therapeutics, Warren, New Jersey, USA; Pluristem Therapeutics Inc., Haifa, Israel; Rooster Bio Inc., Frederick, Maryland, USA; Novartis Pharmaceuticals, Morris Plains, New Jersey, USA; Pall Life Sciences (division of Pall Corp), Port Washington, New York, USA; Stem Cell Group, Bioprocessing Technology Institute, A*STAR, Singapore, Singapore
| | - Knut Niss
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada; Thermo Fisher Scientific, Inc., Grand Island, New York, USA; Celgene Cellular Therapeutics, Warren, New Jersey, USA; Pluristem Therapeutics Inc., Haifa, Israel; Rooster Bio Inc., Frederick, Maryland, USA; Novartis Pharmaceuticals, Morris Plains, New Jersey, USA; Pall Life Sciences (division of Pall Corp), Port Washington, New York, USA; Stem Cell Group, Bioprocessing Technology Institute, A*STAR, Singapore, Singapore
| | - Harvey Brandwein
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada; Thermo Fisher Scientific, Inc., Grand Island, New York, USA; Celgene Cellular Therapeutics, Warren, New Jersey, USA; Pluristem Therapeutics Inc., Haifa, Israel; Rooster Bio Inc., Frederick, Maryland, USA; Novartis Pharmaceuticals, Morris Plains, New Jersey, USA; Pall Life Sciences (division of Pall Corp), Port Washington, New York, USA; Stem Cell Group, Bioprocessing Technology Institute, A*STAR, Singapore, Singapore
| | - Steve Oh
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada; Thermo Fisher Scientific, Inc., Grand Island, New York, USA; Celgene Cellular Therapeutics, Warren, New Jersey, USA; Pluristem Therapeutics Inc., Haifa, Israel; Rooster Bio Inc., Frederick, Maryland, USA; Novartis Pharmaceuticals, Morris Plains, New Jersey, USA; Pall Life Sciences (division of Pall Corp), Port Washington, New York, USA; Stem Cell Group, Bioprocessing Technology Institute, A*STAR, Singapore, Singapore
| | - Ohad Karnieli
- International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada; Thermo Fisher Scientific, Inc., Grand Island, New York, USA; Celgene Cellular Therapeutics, Warren, New Jersey, USA; Pluristem Therapeutics Inc., Haifa, Israel; Rooster Bio Inc., Frederick, Maryland, USA; Novartis Pharmaceuticals, Morris Plains, New Jersey, USA; Pall Life Sciences (division of Pall Corp), Port Washington, New York, USA; Stem Cell Group, Bioprocessing Technology Institute, A*STAR, Singapore, Singapore
| |
Collapse
|